Yan Ya-Xin, Zhou Hua-Miao, Shang Xiao-Guang, Xu Pei, Tang Xiao-Qi, Zheng Xin-Yi, Yu Li-Hua, Li Cheng-Tan, Xie Tian, Lou Jian-Shu
School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, China.
Pharmacol Res. 2025 Jul;217:107815. doi: 10.1016/j.phrs.2025.107815. Epub 2025 Jun 5.
Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, plays a critical role in various pathological conditions, including cancer and organ injury. Post-translational modifications (PTMs) dynamically regulate ferroptosis by modulating the stability, activity, and interactions of key proteins such as GPX4, SLC7A11, and ACSL4. A single protein can undergo multiple PTMs, and the same regulatory enzyme may exert opposing effects on ferroptosis by modifying different proteins. Therefore, a comprehensive analysis of PTMs in regulatory proteins is essential for elucidating their overall impact on ferroptosis. This review systematically examines the roles of ubiquitination, ubiquitin-like modifications (e.g. UFMylation, SUMOylation), alkylation, and succination in ferroptosis regulation. We highlight how E3 ligases, deubiquitinating enzymes (DUBs), and other PTM-associated enzymes modulate ferroptosis by governing the degradation or stabilization of key targets, thereby influencing redox homeostasis and iron metabolism. Clinically, PTM-targeting agents, including E3 ligase modulators and SUMOylation inhibitors, demonstrate therapeutic potential in preclinical models, though their clinical translation remains in its early stages. This review underscores the complexity of PTM-mediated ferroptosis regulation and highlights the need to explore PTM crosstalk, refine therapeutic strategies, and develop novel PTM modulators for the treatment of malignancies and iron-related disorders.
铁死亡是一种由脂质过氧化驱动的铁依赖性调节性细胞死亡形式,在包括癌症和器官损伤在内的各种病理状况中起关键作用。翻译后修饰(PTM)通过调节关键蛋白(如谷胱甘肽过氧化物酶4(GPX4)、溶质载体家族7成员11(SLC7A11)和长链脂酰辅酶A合成酶4(ACSL4))的稳定性、活性和相互作用来动态调节铁死亡。单个蛋白可经历多种PTM,并且相同的调节酶可能通过修饰不同蛋白对铁死亡产生相反的作用。因此,全面分析调节蛋白中的PTM对于阐明它们对铁死亡的总体影响至关重要。本综述系统地研究了泛素化、类泛素修饰(如UFMylation、SUMOylation)、烷基化和琥珀酰化在铁死亡调节中的作用。我们强调了E3连接酶、去泛素化酶(DUB)和其他与PTM相关的酶如何通过控制关键靶点的降解或稳定来调节铁死亡,从而影响氧化还原稳态和铁代谢。在临床上,靶向PTM的药物,包括E3连接酶调节剂和SUMOylation抑制剂,在临床前模型中显示出治疗潜力,尽管它们的临床转化仍处于早期阶段。本综述强调了PTM介导的铁死亡调节的复杂性,并强调需要探索PTM之间的相互作用、完善治疗策略以及开发新型PTM调节剂来治疗恶性肿瘤和铁相关疾病。